Salute e Benessere

Press release Biocartis Group NV: Four Abstracts Showing Excellent Data for…

PRESS RELEASE 20 October 2023, 07:00 CEST Four Abstracts Showing Excellent Data for Idylla™ Presented at European Society of Molecular Oncology Congress (ESMO) Mechelen, Belgium,20 October 2023 –Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company, announces that four study abstracts on Idylla™ have been selected for poster presentations at the international ESMO (European Society of Molecular Oncology) congress, taking place between 20-24...
Nasdaq GlobeNewswire
20/10/2023

Addex Completes ADS Ratio Change

Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, October 20, 2023 - Addex Therapeutics(SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the Company's previously disclosed change to its American Depositary Shares (“ADSs”) to ordinary share ratio has been accepted by Nasdaq and will be effective on October 23, 2023. The ratio will change from one (1) ADS to six (6)...
Nasdaq GlobeNewswire
20/10/2023

DHL Delivers the 1st NASA-Designed Ventilator to Uganda for XRP Healthcare & The…

XRP Healthcare Business Development Officer & Co-founder Laban Roomes said "We chose DHL to ship the first NASA-designed ventilator to Uganda for several key aspects:" XRP Healthcare Business Development Officer & Co-founderLaban Roomessaid "We chose DHL to ship the first NASA-designed ventilator toUgandafor several key aspects:" DHL will play a pivotal role in ensuring the seamless movement of the NASA-designed ventilators from manufacturersSpiritus Medical…
PR Newswire
20/10/2023

Live4Well Brings "Sportive Income" to the Global Stage, Announcing Expansion…

At the summit, Live4Well captured the interest of innovators and industry leaders across the spectrum of Web 3.0, blockchain, cryptocurrency, and NFT sectors. The company seized this opportunity to unveil its innovative concept of "Sportive Income," transforming personal fitness into financial wealth. At the summit,Live4Wellcaptured the interest of innovators and industry leaders across the spectrum of Web 3.0, blockchain, cryptocurrency, and NFT sectors. The company seized this…
PR Newswire
20/10/2023

Myopia Market to Grow at a Substantial Growth Rate During the Study Period…

Key Takeaways from the Myopia Market Report Key Takeaways from the Myopia Market Report Discover which therapies are expected to grab the major myopia market share @Myopia Market Report Myopia Overview Myopia (also known as nearsightedness) is a group of ocular abnormalities characterized by the far point of the eye being closer to the retina than infinity. It is rapidly spreading over the world and posing a significant public health burden. As a result, the worldwide...
PR Newswire
19/10/2023

Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related…

It continued: "The melanocortin receptor 4 (MC4R) market is expected to witness significant growth across various regions, namely North America (NA), Asia Pacific (APAC), Europe, the United States of America (USA), and China. North America, with its well-established healthcare infrastructure and increasing prevalence of obesity-related disorders, is anticipated to dominate the market. The region is projected to hold a substantial market share percent valuation due to the rising obese…
PR Newswire
19/10/2023

VEOS FDA 510(k) clearance

Press release Ecully, October 19, 2023 – 6 p.m. Spineway obtains 510(k) clearance from the FDA for its VEOS spinal fixation system Spineway Group, a specialist in innovative implants for the treatment of severe spinal conditions, is pleased to announce the recent 510(k) clearance from the US Food and Drug Administration (FDA) for its VEOS Spinal Fixation System.This clearance, which allows Spineway Group to market its VEOS system in the US, represents a significant...
Nasdaq GlobeNewswire
19/10/2023

EssilorLuxottica: Q3/9M 2023 Revenue - Sales up 7.2% year-to-date at constant…

Q3/9M 2023 RevenueSales up 7.2%year-to-date at constant currency 1 Keeping the pace of a sound growth Group's revenue up 5.2% in Q3 at constant exchange rates 1 North America in line with the second quarter, supported by opticalEMEA strong, driven by Professional Solutions and optical retailVarilux XR ramping up nicely, Stellest doubled in ChinaSwarovski off to a promising startRay-Ban Meta launched, the next generation of smart glasses ...
Nasdaq GlobeNewswire
19/10/2023

GUERBET : Revenue at 30 September 2023.

Revenue at 30 September 2023Activity9-month revenue: €573.9 million, up 2.7% at CER 1 Third-quarter sales remained very strong in Asia (+15.2% at CER), were stable in EMEA (+0.6%) and showed a smaller decline in the Americas (-5.2%)Expecting double-digit activity growth in the fourth quarter of 2023 thanks to the surge in sales of Elucirem TMand strong momentum in Interventional Imaging Financial targets...
Nasdaq GlobeNewswire
19/10/2023

European Organisation for Research and Treatment of Cancer & the Menarini Group…

ORSERDU® (elacestrant) was approved by the European Commission in September 2023 as a monotherapy for the treatment of postmenopausal women, and men, with estrogen receptor (ER)–positive, HER2-negative, locally advanced or metastatic breast cancer (mBC) with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK4/6 inhibitor. ORSERDU® (elacestrant) was approved by the European Commission inSeptember 2023as a monotherapy for...
PR Newswire
19/10/2023

eMed Healthcare UK promises continuity and expansion following successful…

"This is a new era for the company and for digital-first primary care in the UK." said Dr Patrice Harris, co-founder and CEO of eMed. She added: "Our focus for eMed Healthcare UK will be clinical excellence, high quality care, customer service and redefining chronic care management. We are totally committed to all of our patients, NHS and private, and our vision will be powered by people and enabled by digital technology." " This is a new era for the company and for…
PR Newswire
19/10/2023

Artificial Intelligence (AI) in Medical Diagnostics Market Worth $3.7 billion |…

However, Inadequate AI workforce and ambiguous regulatory guidelines for medical software are factors expected to restrain the market growth. However, Inadequate AI workforce and ambiguous regulatory guidelines for medical software are factors expected to restrain the market growth. Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=22519734 Browse in-depth TOC on "Artificial Intelligence (AI) in Medical Diagnostics Market" 401 - Tables ...
PR Newswire
19/10/2023

Rising Awareness about Sustainable Practices to Push Refillable Deodorants…

The global refillable deodorants market value is estimated to reach US$ 188.9 million in 2023 and US$ 325 million by 2033. Over the assessment period, global sales of refillable deodorants are likely to surge at 5.6% CAGR. The global refillable deodorants market value is estimated to reach US$ 188.9 million in 2023 and US$ 325 million by 2033. Over the assessment period, global sales of refillable deodorants are likely to surge at5.6% CAGR. Sales of refillable spray deodorants are...
PR Newswire
19/10/2023

Electric Wheelchair Market Size to Grow USD 1850 Million by 2029 at a CAGR of…

Major Factors Driving the Growth Of Electric Wheelchair Market Major Factors Driving the Growth Of Electric Wheelchair Market The demand for electrical wheelchairs is rising, which has increased the need for technological advancements. This is explained by the necessity for equipment to be stronger and more resilient in order to support the weight of fat people. Automated movement systems have been created as a result of technology advancements, which limit the human interventions of...
PR Newswire
19/10/2023

Wolters Kluwer Applauded by Frost & Sullivan for Improving Healthcare…

Wolters Kluwer's Emmi leverages conversational AI to enable patients to be a participant in their health care while reducing the burden on the clinician side. For example, Emmi's conversational AI can support a follow up call to a patient that has been diagnosed with Covid to see how they are recuperating. By asking and answering questions, the conversational AI can connect a patient who is not feeling better or has a fever, with a doctor's office. Conversational AI can also support outreach for…
PR Newswire
19/10/2023

Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Marburg Vaccine in…

WASHINGTON, Oct.19, 2023(GLOBE NEWSWIRE) -- The Sabin Vaccine Institute has launched a Phase 2 clinical trial for its vaccine candidate against the lethal Marburg virus. Healthy volunteers received the single-dose vaccine at Makerere University Walter Reed Project (MUWRP) in Kampala, Uganda today. There are currently no vaccines or antiviral treatments approved to treat Marburg virus disease. Marburg is a filovirus, in the same family as the virus that causes Ebola. Like Ebola,...
Nasdaq GlobeNewswire
19/10/2023

Flo for Partners Now Available: Unlocking Better Sex, Conception and…

A recent survey, conducted by Flo, which included 1.8K UK men aged 18-50 further highlights the need for education and open communication, with findings pointing to stark knowledge gaps among men: A recent survey, conducted by Flo, which included1.8KUK men aged 18-50 further highlights the need for education and open communication, with findings pointing to stark knowledge gaps among men: The lack of knowledge, misinformation and poor communication can also lead to a sexual disconnect...
PR Newswire
19/10/2023

Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for…

Investigational New Drug (IND) application planned in first half of 2024 Investigational New Drug (IND) application planned in first half of 2024 SAN DIEGO,HOUSTONandSINGAPORE,Oct. 19, 2023/PRNewswire/ -- Hummingbird Bioscience ("Hummingbird Bio"), a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, and Endeavor BioMedicines ("Endeavor"), a clinical-stage company targeting the drivers of...
PR Newswire
19/10/2023

PRODUCTLIFE GROUP ACQUIRES STRATEGIQUAL, REINFORCING ITS POSITION AS QUALITY &…

Florent Audureau, Chairman of Strategiqual, commented: "Since our creation, we have been providing expert regulatory solutions to assist our customers in market access and maintenance of their products. By joining PLG, we are strategically complementing each other's solutions, being now able to cover the complete lifecycle of healthcare products, at French, European and international levels." Florent Audureau, Chairman of Strategiqual, commented: "Since our creation, we have been…
PR Newswire
19/10/2023

Waters Accelerates Oligonucleotide Bioanalysis with the Launch of OligoWorks™…

The pipeline for oligonucleotide therapeutics is rapidly expanding with thirteen FDA approved oligonucleotide therapeutics today, and 500+ in the pipeline. While potent, these highly modified oligonucleotides are challenging to precisely quantify during dosing, metabolism, and tissue distribution studies. The pipeline for oligonucleotide therapeutics is rapidly expanding with thirteen FDA approved oligonucleotide therapeutics today, and 500+ in the pipeline. While potent, these highly…
PR Newswire
19/10/2023

Viralgen welcomes back Andy Holt as CCO

Holt brings more than 15 years of experience in cell and gene therapy into his new role. His most recent position was CCO of Ncardia and Cellistic, affiliated companies leveraging deep experience in induced pluripotent stem cell (iPSC) technology to accelerate drug discovery and allogeneic cell therapy development. Prior to his first role with Viralgen, Holt held business development and management positions at MilliporeSigma (Merck KGaA) and Lonza."Viralgen has always worked hard to…
Nasdaq GlobeNewswire
19/10/2023

Qilu Pharmaceutical to Showcase Novel Anti-Cancer Drug QL1706 at ESMO Congress…

I. Phase II Clinical Trial of QL1706 I. Phase II Clinical Trial of QL1706 Combination immunotherapy has emerged as the first-line treatment approach for recurrent/metastatic CC. Qilu Pharmaceutical's class 1 novel drug, QL1706, is a bifunctional antibody that simultaneously targets PD-1 and CTLA-4, producing synergistic anti-tumor effects. The phase Ib clinical trial of QL1706 for advanced solid tumors has confirmed the drug's promising efficacy of monotherapy in patients with advanced...
PR Newswire
19/10/2023

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD)…

Late-breaking Phase 1b data assesses the clinical outcomes of reducing tau in patients with early-stage Alzheimer's diseaseAdditional late-breaking presentations from the CLARITY AD study explore predictive biomarkers and novel subcutaneous administration of LEQEMBI ®(lecanemab-irmb) CAMBRIDGE, Mass., Oct.19, 2023(GLOBE NEWSWIRE) --BiogenInc. (Nasdaq: BIIB) will present new data from its Alzheimer's disease portfolio at the upcoming Clinical Trials on Alzheimer's Disease (CTAD)...
Nasdaq GlobeNewswire
19/10/2023

Instrumentation Valve and Fitting Market to reach US$ 5.1 billion by 2033 as…

By 2033, instrumentation valves and fittings sales are projected to be worth about US$ 5.1 billion. In the forecast period, the instrumentation valve and fitting space are expected to generate a total financial potential of US$ 2.4 billion. By 2033, instrumentation valves and fittings sales are projected to be worth aboutUS$ 5.1 billion. In the forecast period, the instrumentation valve and fitting space are expected to generate a total financial potential ofUS$ 2.4 billion...
PR Newswire
19/10/2023
Altri  Comunicati